Intuitive Surgical has seen its share price swing sharply in recent years, and the question now is whether the current US$422.06 level is supported by the cash the business can generate. Recent competitive news has sharpened that focus, since investors are being asked to pay today for cash flows that will play out over many years.
- Over the past 3 years the stock has gained 53.3%, which puts a lot of weight on whether those cash flows can keep justifying a richer price tag than in the past.
- The FDA marketing authorization of Johnson & Johnson's OTTAVA robotic system introduces a fresh rival that may influence how quickly Intuitive Surgical can grow its installed base and future cash inflows.
- If you'd rather focus on earnings, this one's for you. See why Intuitive Surgical's 47.5x P/E tells a different valuation story.
The stock's next move may depend on whether Intuitive Surgical's current cash flows and their projected path are strong enough to support today's share price.
If you want more than a single stock in your research pipeline, a focused screen of surgical robotics and automation plays can be a useful second step, starting with 90 robotics and automation stocks.
Where Does Intuitive Surgical Sit on Cash Flow?
The Discounted Cash Flow (DCF) model here focuses on the cash Intuitive Surgical can return to shareholders over time. Latest twelve month free cash flow sits at about $2.7b, and the projections used in the model point to growing cash generation over the coming decade rather than a shrinking profile. That growth path is what needs to carry the current US$422.06 share price.
The DCF inputs rely on a mix of analyst forecasts and gradual growth estimates in later years. This approach fits a business that already produces sizable free cash but is still investing to expand its installed base. Johnson & Johnson’s OTTAVA approval helps explain why the current valuation already prices in meaningful competitive pressure, even though the cash flow outlook in the model still supports a level broadly in line with today’s market price. Find out what Intuitive Surgical could be worth using our Discounted Cash Flow (DCF) estimate.
The Intuitive Surgical Narrative: What Would Justify Today's Price?
Narratives on Simply Wall St act as the missing link between Intuitive Surgical's current valuation puzzle and the specific assumptions that would need to hold on growth, margins and earnings for the stock to end up meaningfully above or below today's share price. Each scenario ties a fair value to a clear storyline about Intuitive Surgical's potential catalysts and key risks, so you can track over time which version of events appears to be unfolding on the Community page.
Community views on Intuitive Surgical are now split between a fair-value story built on its ecosystem and a more cautious stance focused on margin pressure and competition.
Bull case: 21% undervalued
"This high number of procedures ensures a strong demand for replacement parts and services, which now account for 83% of Intuitive’s total revenue…"
Discover why this Narrative puts Intuitive Surgical at 21% undervalued.
Bear case: 30% overvalued
"Bearish analysts expect Intuitive Surgical to experience sustained margin pressure as pricing competition, policy headwinds and new robotic entrants compress returns on its growing installed base…"
Explore why this Narrative puts Intuitive Surgical at 30% overvalued.
For Intuitive Surgical, the share price is only one piece of the puzzle
Before you weigh Intuitive Surgical purely on cash flows and scenarios, it is worth asking who is steering the business, how they are rewarded, and what that implies for your interests as a shareholder. See who runs Intuitive Surgical and how they are paid.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com